Pharmacokinetics of Teicoplanin in An ICU Population of Children and Infants
Purpose. Better dosing is needed for antibiotics, including teicoplanin (TEI), to prevent emergence of resistant bacterial strains. Here, we assess the TEI pharmacokinetics (PK) related to a 10 mg/l minimum inhibitory concentration (MIC) target in ICU children (4 to 120 months; n = 20) with gram+ infections.
Methods. Standard administration of TEI was with three 10 mg/kg Q12h, loading infusions, and maintainance with 10 mg/kg or 15 mg/kg Q24h. During maintenance, 9 samples (3/day) were collected per patient and the PK analyzed with Nonlinear Mixed Effects Model (NONMEM).
Results. Thirty-five percent of concentrations in older children (≥2 months) vs. 8% in younger infants (<12 months) were below the target MIC. The global bicompartmental population PK parameters were [mean (interindividual CV%)] CL = 0.23 l/h [72%], V = 3.16 l [58%], k12 = 0.23 h−1, and k21 = 0.04 h−1. Two PK subpopulations were identified. The older children had CL = 0.29 [23%] l/h, V = 3.9 l and the younger infants, CL = 0.09 [37%] l/h, V = 1.05 l. Residual error was reduced from 52% to around 30% in the final models.
Conclusions. Older children in the ICU may require relatively higher doses of teicoplanin. However, a study in a larger population is needed.
children infants NONMEM pharmacokinetics simulation teicoplanin
H. Wisplinghoff, H. Seifert, S. M. Tallent, T. Bischoff, R. P. Wenzel, and M. B. Edmond. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J.
:686–691 (2003).PubMedGoogle Scholar
H. M. Aucken, M. Ganner, S. Murchan, B. D. Cookson, and A. P. Johnson. A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J. Antimic. Chemother.
:171–175 (2002).Google Scholar
A. P. Johnson, C. Henwood, S. Mushtaq, D. James, M. Warner, and D. M. Livermore. ICU Study Group. Susceptibility of gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. J. Hosp. Infect.
:179–187 (2003).PubMedGoogle Scholar
J. Cepeda, S. Hayman, T. Whitehouse, C. C. Kibbler, D. Liver-more, M. Singer, and A. P. Wilson. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J. Antimicrob. Chemother.
:533–534 (2003).PubMedGoogle Scholar
J. M. Hamilton-Miller. Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infecion
:118–124 (2002).Google Scholar
G. L. Drusano. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis.
1)):42–50 (2003).Google Scholar
G. L. Traina and M. Bonati. Pharmacokinetics of teicoplanin in man after intravenous administration. J. Pharmacokinet. Biopharm.
:119–128 (1984).PubMedGoogle Scholar
J. D. Knudsen, K. Fuursted, S. Raber, F. Espersen, and N. Frimodt Moller. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother.
:1247–1254 (2000).PubMedGoogle Scholar
P. Vaudaux, P. Francois, B. Berger-Bachi, and D. P. Lew. In vivo
emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible methicillin-resistant strain of Staphylococcus aureus. J. Antimicrob. Chemother.
:163–170 (2001).PubMedGoogle Scholar
M. Rowland. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet.
:184–209 (1990).PubMedGoogle Scholar
A. P. Wilson. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet.
:167–183 (2000).PubMedGoogle Scholar
V. Fanos, M. Mussap, B. J. Khoory, S. Vecchini, M. Plebani, and D. Benini. Renal tolerability of teicoplanin in a case of neonatal overdose. J. Chemother.
:381–384 (1998).PubMedGoogle Scholar
A. Louie, P. Kaw, W. Liu, N. Jumpe, M. H. Miller, and G. L. Drusano. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus
infection. Antimicrob. Agents Chemother.
:845–851 (2001).PubMedGoogle Scholar
N. Jauregizar, J. A. Wald, A. Astobieta, J. M. Rodriguez Sasiain, J. C. Lucas, and R. Calvo. Population pharmacokinetics of netilmicin in short term prophylactic treatment. Br. J. Clin. Pharmacol.
:552–559 (2003).PubMedGoogle Scholar
A. Sanchez, J. Lopez-Herce, E. Cueto, A. Camllo, and R. Moral. Teicoplanin pharmacokinetics in critically ill paediatric patients. J. Antimicrob. Chemother.
:407–409 (1999).PubMedGoogle Scholar
D. R. Butler, R. J. Kuhn, and M. H. Chandler. Pharmacokinetics of anti-infective agents in paediatric patients. Clin. Pharmacokinet.
:374–395 (1994).PubMedGoogle Scholar
R. F. Reinoso, B. A. Telfer, B. S. Brennan, and M. Rowland. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab. Dispos.
:453–459 (2001).PubMedGoogle Scholar
© Springer Science+Business Media, Inc. 2004